vs
Phoenix Education Partners, Inc.（PXED）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Phoenix Education Partners, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$222.5M vs $207.3M），Phoenix Education Partners, Inc.净利率更高（4.8% vs -62.0%，领先66.9%），Phoenix Education Partners, Inc.自由现金流更多（$43.5M vs $-100.8M）
凤凰城大学是总部位于美国亚利桑那州凤凰城的私立营利性大学，由凤凰城教育合伙公司持有，1976年成立，可颁发证书及副学士、学士、硕士、博士多个层级的学位。该校获高等教育委员会官方认证，不少本科项目实行开放入学政策。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PXED vs RARE — 直观对比
营收规模更大
PXED
是对方的1.1倍
$207.3M
净利率更高
PXED
高出66.9%
-62.0%
自由现金流更多
PXED
多$144.3M
$-100.8M
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $222.5M | $207.3M |
| 净利润 | $10.8M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 6.3% | -54.7% |
| 净利率 | 4.8% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.28 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PXEDRARE
| Q1 26 | $222.5M | — | ||
| Q4 25 | $262.0M | $207.3M | ||
| Q3 25 | — | $159.9M | ||
| Q2 25 | — | $166.5M | ||
| Q1 25 | — | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | — | $139.5M | ||
| Q2 24 | — | $147.0M |
净利润PXEDRARE
| Q1 26 | $10.8M | — | ||
| Q4 25 | $15.5M | $-128.6M | ||
| Q3 25 | — | $-180.4M | ||
| Q2 25 | — | $-115.0M | ||
| Q1 25 | — | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | — | $-133.5M | ||
| Q2 24 | — | $-131.6M |
营业利润率PXEDRARE
| Q1 26 | 6.3% | — | ||
| Q4 25 | 9.8% | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% |
净利率PXEDRARE
| Q1 26 | 4.8% | — | ||
| Q4 25 | 5.9% | -62.0% | ||
| Q3 25 | — | -112.8% | ||
| Q2 25 | — | -69.0% | ||
| Q1 25 | — | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | — | -95.7% | ||
| Q2 24 | — | -89.5% |
每股收益（稀释后）PXEDRARE
| Q1 26 | $0.28 | — | ||
| Q4 25 | $0.40 | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.4M | $421.0M |
| 总债务越低越好 | $58.8M | — |
| 股东权益账面价值 | $291.1M | $-80.0M |
| 总资产 | $546.4M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资PXEDRARE
| Q1 26 | $201.4M | — | ||
| Q4 25 | $163.5M | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
总债务PXEDRARE
| Q1 26 | $58.8M | — | ||
| Q4 25 | $61.6M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PXEDRARE
| Q1 26 | $291.1M | — | ||
| Q4 25 | $280.4M | $-80.0M | ||
| Q3 25 | — | $9.2M | ||
| Q2 25 | — | $151.3M | ||
| Q1 25 | — | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | — | $346.8M | ||
| Q2 24 | — | $432.4M |
总资产PXEDRARE
| Q1 26 | $546.4M | — | ||
| Q4 25 | $549.6M | $1.5B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B |
负债/权益比PXEDRARE
| Q1 26 | 0.20× | — | ||
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $43.5M | $-100.8M |
| 自由现金流率自由现金流/营收 | 19.6% | -48.6% |
| 资本支出强度资本支出/营收 | 2.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.53× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流PXEDRARE
| Q1 26 | $48.9M | — | ||
| Q4 25 | $31.1M | $-99.8M | ||
| Q3 25 | — | $-91.4M | ||
| Q2 25 | — | $-108.3M | ||
| Q1 25 | — | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | — | $-67.0M | ||
| Q2 24 | — | $-77.0M |
自由现金流PXEDRARE
| Q1 26 | $43.5M | — | ||
| Q4 25 | $26.4M | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
自由现金流率PXEDRARE
| Q1 26 | 19.6% | — | ||
| Q4 25 | 10.1% | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
资本支出强度PXEDRARE
| Q1 26 | 2.4% | — | ||
| Q4 25 | 1.8% | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
现金转化率PXEDRARE
| Q1 26 | 4.53× | — | ||
| Q4 25 | 2.01× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PXED
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
